Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COL-3 in Recurrent High-Grade Astrocytoma
NCT00004147Phase 2Completed
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
- Start
- Jul 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of incyclinide in anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO) and glioblastoma (GBM), sponsored by New Approaches to Brain Tumor Therapy Consortium. Primary endpoints: Maximum Tolerated Dose, Dose Limiting Toxicity and 1 more. Started Jul 2000; status: completed.
02
Drugs
incyclinide
03
Conditions
anaplastic astrocytoma (AA)anaplastic oligodendroglioma (AO)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00004147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004147.